Veralto puts $465m on Cleanwater1 and extends its Water Quality franchise

On 19 August 2026, Veralto (NYSE: VLTO) announced it had entered into a definitive agreement to acquire Cleanwater1 for $465 million, subject to customary closing adjustments.¹ After considering estimated tax benefits, the net purchase price is approximately $452 million. Closing is expected in the fourth quarter of 2026, subject to customary closing conditions.

Cleanwater1 is a provider of on-site hypochlorite disinfection, solids management and odor filtration technologies, with an installed base of approximately 25,000 units across municipal drinking water, wastewater and industrial applications.¹ Veralto framed the business as complementary to its existing water treatment portfolio and as an expansion into adjacent, high-growth water treatment applications within the Water Quality segment.

Over the last twelve months ended 30 June 2026, Cleanwater1 generated approximately $135 million in sales, of which about 25% were aftermarket sales.¹ Since 2023, Cleanwater1's sales have grown at a compound annual growth rate in the low double-digits. Veralto expects Cleanwater1's sales to continue growing in the low double-digits over the next few years, leveraging Trojan Technologies customer relationships, servicing the installed base, and applying the Veralto Enterprise System (VES) commercial tools.

The announcement lands in an active August 2026 M&A window alongside Munich Re's $575 million At-Bay agreement and Bending Spoons' $1.285 billion Airtable transaction. For water technology specifically, Veralto's deal is a public-company statement that installed-base disinfection and solids platforms with aftermarket density remain strategic bolt-ons even when headline multiples look rich on an EBITDA basis.

Veralto disclosed purchase price, net purchase price after estimated tax benefits, an EBITDA multiple on the net price, LTM sales, aftermarket mix, growth language, EPS and ROIC outlook, and expected close timing. Absolute LTM adjusted EBITDA dollars, cash versus stock mix, retention pools, and earn-outs were not published in the 19 August release.¹ For a private water-tech exit to a strategic industrial buyer, headline price and the stated multiple are the anchors analysts and founders will cite first.

What we know from primary sources:

• Purchase price: $465 million (customary closing adjustments)
• Net purchase price: approximately $452 million after estimated tax benefits
• Multiple: ~17× Cleanwater1 LTM adjusted EBITDA as of 30 June 2026 (on $452M net; no synergies in the multiple)
• Target scale: ~$135M LTM sales; ~25% aftermarket
• Installed base: ~25,000 units (municipal drinking water, wastewater, industrial)
• Timing: Expected close Q4 2026, customary conditions pending
• EPS / ROIC: Neutral to modestly accretive to adjusted EPS in 2027; ROIC at or above WACC by year four

Water utilities and industrial operators do not buy disinfection gear as a one-time novelty. They buy systems that must run every day under regulatory pressure, safety constraints, and tight operating budgets. Cleanwater1's disclosed mix of on-site hypochlorite generation, solids management and odor filtration sits inside that daily operating stack. An installed base of roughly 25,000 units is not only a sales proof point; it is a serviceable fleet for aftermarket chemicals, parts, monitoring and upgrades. Veralto already flags aftermarket at about 25% of LTM sales, which is the seed of the recurring-revenue expansion thesis in the release.¹

The strategic adjacency is explicit: Cleanwater1 is complementary to Veralto's existing water treatment portfolio, with "clearly identified commercial synergies" between Cleanwater1 and Trojan Technologies ultraviolet water treatment solutions.¹ UV and on-site chlorine are not the same product category, but they often address overlapping municipal and industrial customer sets. Veralto's bet is that Trojan relationships can accelerate Cleanwater1's growth rate while VES commercial tools and installed-base servicing deepen wallet share. That is a classic industrial platform move: add a high-touch application franchise next to an existing treatment brand, then compound through shared routes to market.

Water treatment M&A in 2026 rewards platforms that sit inside regulated daily operations, not optional analytics layers. On-site hypochlorite, solids management and odor control are CapEx-plus-OpEx businesses: equipment sale first, then chemicals, parts, service and compliance support. Veralto's emphasis on recurring revenue expansion from a ~25,000-unit base is a template other strategics will cite when screening disinfection and solids assets.

The pricing signal is the combination of $465 million / ~$452 million net and ~17× LTM adjusted EBITDA without synergies in the multiple.¹ Sellers with similar aftermarket mix and municipal-industrial footprints now have a fresh strategic comp. Buyers without UV or chlorine adjacency will struggle to justify the same multiple unless they can narrate an equally specific commercial synergy path.

Industrial change-of-control transactions typically move through customary closing conditions, integration planning, and post-close operating model announcements. Veralto expects completion in the fourth quarter of 2026, a shorter window than many cross-border insurance or software deals announced the same week.¹ That timeline implies confidence in conditions but still leaves room for standard antitrust and contractual closing mechanics.

Until close, Veralto and Cleanwater1 operate under ordinary interim covenants. Municipal and industrial customers should expect continuity of supply and service for Polyblend, Dynablend, Veloblend, PAX Mixers, Monoclor RCS, Microclor OSHG and I-Box Odor Control offerings. Integration teams will likely work behind the scenes on commercial routing with Trojan Technologies, VES tooling rollouts, and aftermarket playbooks across the ~25,000-unit installed base.

Post-close, Acquiry will watch three disclosed levers: (1) whether Cleanwater1 growth remains in the low double-digits as Veralto guided, (2) whether recurring and aftermarket mix rises from the ~25% LTM base, and (3) whether adjusted EPS and ROIC track the 2027 neutrality-to-modest accretion and year-four ROIC-at-or-above-WACC framing.¹ Earnings calls for VLTO may quantify synergy spend and Water Quality segment contribution once the business is inside reported results.

Competitors in chlorine disinfection, polymer blending and odor control should expect sharper Veralto packaging in municipal RFPs that previously treated UV and chemical systems as separate vendor decisions. Channel partners tied only to Cleanwater1 brands may see Veralto procurement and pricing discipline arrive with VES. Talent retention through close will signal how aggressively Veralto intends to keep application engineering depth versus consolidating brands into fewer commercial teams.

Regulatory and disclosure follow-through may include Form 8-K updates, purchase accounting detail, and any refinement of tax benefit estimates that move the net price away from the ~$452 million figure. Absolute EBITDA dollars remain undisclosed at announcement; later filings or investor decks may allow a reverse-engineered EBITDA print from the 17× statement. Until then, Deal Intelligence will keep the multiple labelled exactly as Veralto defined it.

Acquiry will update this report when primary sources publish closing confirmation, amended financial disclosures, or post-close integration plans. Continuous reporting is core to Deal Intelligence: transaction pages are living documents, not static press summaries.

Acquiry's read is that Veralto paid for an installed-base water platform with aftermarket density, not for a standalone equipment catalogue. Cleanwater1's combination of ~$135 million LTM sales, ~25% aftermarket, ~25,000 units, and explicit Trojan adjacency gave Veralto something organic R&D cannot assemble quickly: application expertise across hypochlorite, solids and odor, already embedded in municipal and industrial daily operations.

Three structural forces make this deal more than a mid-market industrial headline. First, buyer type: Veralto is a public Water Quality strategic with ~$5.5 billion of annual sales and a named operating system (VES). That changes seller dynamics versus private equity. Earn-outs tied to rapid margin expansion may give way to multi-year commercial integration and ROIC gates. Honeycutt's recurring-revenue language and the year-four ROIC commitment are the negotiation tells.

Second, adjacency economics. The release does not invent a vague "water synergy." It names Trojan Technologies ultraviolet relationships as a commercial accelerator and excludes those synergies from the ~17× multiple. That is how sophisticated strategics sell deals to investors: show the growth path, keep the multiple clean. Sellers should ask every bidder to separate "walk-away multiple" from "with-synergy underwriting."

Third, multiple realism without invented EBITDA. Because Veralto did not publish absolute LTM adjusted EBITDA, outsiders should not invent it. The disclosed facts are enough for process design: $465 million headline, ~$452 million net, ~17× on the net price, ~$135 million sales, low double-digit growth. Founders who force a reverse-engineered EBITDA into banker books without primary support create diligence risk. Use the disclosed bridge; label everything else as estimate.

For shareholders exploring a sale in water disinfection, solids, odor control or adjacent treatment hardware, the live Deal Intelligence comparable set now spans Cleanwater1 ($465M to Veralto), At-Bay ($575M EV to Munich Re), and Airtable ($1.285B EV to Bending Spoons). Each reflects a different thesis. All reward defensible recurring or underwriting economics and production data, not roadmap slides.

Segment mix will matter after close. If Cleanwater1's aftermarket and service attach rise under VES, Veralto can defend the entry multiple with quality of revenue rather than peak equipment years. If growth stalls at low double-digits without mix shift, the 17× print becomes a harder investor conversation. That is the operating test behind the EPS and ROIC guidance.

If you are evaluating a sale in water treatment technology, disinfection hardware, or municipal-industrial process equipment, this transaction is a useful comp for both valuation framing and buyer mapping. Acquiry tracks strategic mandates through our Deal Intelligence programme and sell-side advisory work across the acquisitions hub.